Clinical trials: Enoxaparin
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- RECORD 2 (NCT00332020)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 126 sites in United States, Australia and 21 more
- Volunteers
- 2,457 people
- Sponsor
- Bayer
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 3 (NCT00361894)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 143 sites in Austria, Belgium and 17 more
- Volunteers
- 2,531 people
- Sponsor
- Bayer
Pulmonary Embolism
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary…
- Trial name
- NCT00439777
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
- Where
- 305 sites in United States, Andorra and 37 more
- Volunteers
- 4,833 people
- Sponsor
- Bayer
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited
Cardiac Disease
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment.
- Trial name
- NCT03395639
- Testing
- Edoxaban, Standard of Care (SOC)
- Where
- 48 sites in United States, Austria and 12 more
- Volunteers
- 168 people
- Sponsor
- Daiichi Sankyo
Arthroplasty, Replacement, Knee
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or…
- Trial name
- AXIOMATIC-TKR (NCT03891524)
- Testing
- JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg
- Where
- 117 sites in United States, Argentina and 16 more
- Volunteers
- 1,242 people
- Sponsor
- Janssen Research & Development, LLC
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Healthy
Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants
The study will assess the distribution and variability of whole blood clotting time (WBCT) measurement in human blood collected from healthy volunteers that is untreated and spiked with predetermined concentrations of edoxaban or…
- Trial name
- NCT03296982
- Testing
- Blood drawn by direct venipuncture, edoxaban, Enoxaparin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Venous Thromboembolism, Arthroplasty, Replacement
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee…
- Trial name
- NCT01153698
- Testing
- dabigatran
- Where
- 7 sites in Austria
- Volunteers
- 167 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Knee Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01206972
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 33 sites in Japan
- Volunteers
- 302 people
- Sponsor
- Bayer
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.
- Trial name
- NCT00917254
- Testing
- YM150, Enoxaparin
- Where
- 13 sites in Japan, Taiwan and 1 more
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Atrial Fibrillation
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin.
- Trial name
- ENSURE-AF (NCT02072434)
- Testing
- Edoxaban, Warfarin, Enoxaparin
- Where
- 228 sites in United States, Austria and 17 more
- Volunteers
- 2,199 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism (VTE)
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.
- Trial name
- ROXI-APEX (NCT07015905)
- Testing
- REGN7508, Apixaban, Enoxaparin
- Where
- 47 sites in United States, Bulgaria and 6 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Thrombotic Disorders
Prevention of Thromboembolic Events in Total Knee Replacement Patients
The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)
- Trial name
- NCT03393481
- Testing
- MAA868, Enoxaparin
- Sponsor
- Novartis Pharmaceuticals
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.
- Trial name
- NCT06220123
- Testing
- SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03551730
- Testing
- PRT064445/Enoxaparin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Arthroplasty, Replacement, Knee, Thromboembolism
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s [150 or 220 mg once daily…
- Trial name
- NCT00168805
- Testing
- enoxaparin, dabigatran etexilate
- Where
- 105 sites in Australia, Austria and 13 more
- Volunteers
- 2,101 people
- Sponsor
- Boehringer Ingelheim